TY - JOUR
T1 - Strategies for inducing effective neutralizing antibody responses against HIV-1
AU - del Moral-Sánchez, Iván
AU - Sliepen, Kwinten
PY - 2019/11
Y1 - 2019/11
N2 - Introduction: Despite intensive research efforts, there is still no effective prophylactic vaccine available against HIV-1. Currently, substantial efforts are devoted to the development of vaccines aimed at inducing broadly neutralizing antibodies (bNAbs), which are capable of neutralizing most HIV-1 strains. All bNAbs target the HIV-1 envelope glycoprotein (Env), but Env immunizations usually only induce neutralizing antibodies (NAbs) against the sequence-matched virus and not against other strains. Areas covered: We describe the different strategies that have been explored to improve the breadth and potency of anti-HIV-1 NAb responses. The discussed strategies include the application of engineered Env immunogens, optimization of (bNAb) epitopes, different cocktail and sequential vaccination strategies, nanoparticles and nucleic acid-based vaccines. Expert opinion: A combination of the strategies described in this review and future approaches are probably needed to develop an effective HIV-1 vaccine that can induce broad, potent and long-lasting NAb responses.
AB - Introduction: Despite intensive research efforts, there is still no effective prophylactic vaccine available against HIV-1. Currently, substantial efforts are devoted to the development of vaccines aimed at inducing broadly neutralizing antibodies (bNAbs), which are capable of neutralizing most HIV-1 strains. All bNAbs target the HIV-1 envelope glycoprotein (Env), but Env immunizations usually only induce neutralizing antibodies (NAbs) against the sequence-matched virus and not against other strains. Areas covered: We describe the different strategies that have been explored to improve the breadth and potency of anti-HIV-1 NAb responses. The discussed strategies include the application of engineered Env immunogens, optimization of (bNAb) epitopes, different cocktail and sequential vaccination strategies, nanoparticles and nucleic acid-based vaccines. Expert opinion: A combination of the strategies described in this review and future approaches are probably needed to develop an effective HIV-1 vaccine that can induce broad, potent and long-lasting NAb responses.
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85075932574&origin=inward
UR - https://www.ncbi.nlm.nih.gov/pubmed/31791150
U2 - https://doi.org/10.1080/14760584.2019.1690458
DO - https://doi.org/10.1080/14760584.2019.1690458
M3 - Review article
C2 - 31791150
SN - 1476-0584
VL - 18
SP - 1127
EP - 1143
JO - Expert Review of Vaccines
JF - Expert Review of Vaccines
IS - 11
ER -